Advanced Search


Study ID Status Title Patient Level Data
APV10023 Completed A Pivotal, Phase I, Open-label, Randomized, Four-Period, Single and Multiple Dose, Crossover Study to Assess the Bioequivalence of Two GW433908 700mg Oral Film-coated Tablet Variants Following Administration of Single 1400mg Doses and Following Administration of 1400mg BID for 14 Days…
APV10024 Completed A Pivotal, Phase I, Open-label, Randomized, Four-Period, Two-Part, Crossover Study to Assess the Relative Bioavailability of the Fosamprenavir 50mg/mL Oral Suspension and 700mg Oral Film-coated Tablet Formulations Following Administration of Single 1400mg Doses and Following Administration of 14 ...
APV10025 Completed A Phase I, Randomized, Open Label, Two Period, Two Sequence, Drug-Drug Interaction Study Comparing Steady-State Plasma Rifabutin Pharmacokinetics following Coadministration of Fosamprenavir 700mg + Ritonavir 100mg Twice Daily (BID) and Rifabutin 150mg Every Other Day (QOD) and following Administ ...
APV10026 Completed A Phase I, Open-Label, Single-Sequence, Drug-Drug Interaction Study Comparing Ketoconazole and Amprenavir Pharmacokinetics Following Administration of Ketoconazole 200 mg QD for Four Days, Fosamprenavir 700mg BID + Ritonavir 100mg BID for Ten Days, and Ketoconazole 200 mg QD + Fosamprenavir 700m ...
APV10028 Completed A Phase I, Open, Randomized, Balanced, Three-Period, Crossover, Steady-State, Pharmacokinetic Study Comparing GW433908 1400mg BID + RTV 100mg BID, GW433908 1400mg BID + RTV 200mg BID, and GW433908 700mg BID + RTV 100mg BID Regimens in Healthy Adult Subjects
APV10029 Completed A Phase I, Open-label, Randomized, Two-Period, Balanced Crossover, Study to Compare Steady-State Plasma Amprenavir Pharmacokinetics following administration of Two GW433908 Tablet Variants, Each administered as 1400mg QD in Combination with Ritonavir 200mg QD in Healthy Adult Subjects
APV10031 Completed A Phase I, Randomized, Open Label, Two Arm, Three Period, Drug-Drug Interaction Study Comparing Steady-State Plasma Amprenavir and Esomeprazole Pharmacokinetics following Coadministration of GW433908 1400mg BID and Esomeprazole 20mg QD and following Coadministration of GW433908 700mg BID + RTV 1 ...
APV102002 Completed A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure
APV109141 Completed Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.
APV20001 Completed Open-Label Phase Report of: A Randomized, Multicenter, Partially Double-Blinded, Repeat Dose, Cross-Over Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Effect of Two Doses of FPV Compared with AGENERASE(1200mg BID) when Given for 28 Days to Subjects Infected with HIV-1
APV20002 Active, Not Recruiting A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced pediatric subjects aged 4 weeks to <2 years.
APV29005 Completed A 48 Week, Phase II, Non-Comparative, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir BID when Administered to HIV-1 infected, PI-Naïve and Experienced, Pediatric Subjects, 2 to 18 Years Old and of GW433908 BID Administered to PI-Naïve, Pediatric Subjects 2 to < 6 Years Old
APV30001 Completed A Phase III, Randomized, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety and Tolerability of GW433908 (1400mg BID) and Nelfinavir (1250mg BID) Over 48 Weeks in Antiretroviral Therapy-Naïve HIV-1 Infected Adults
APV30002 Completed A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination with Abacavir and Lamivudine BID for 48 Weeks in Antiretroviral Therapy Naïve HIV-1 Infected Subjects
APV30003 Completed A Phase III, Randomized, Multicenter, Parallel Group, Open-label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/ritonavir (700mg/100mg twice daily or 1400mg/200mg once daily) versus lopinavir/ritonavir (400mg/100mg twice daily) for 48 Weeks in Protease Inh ...
APV30005 Completed An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects
APV30007 Completed A 24 week Phase IIIb/IV single arm open label observational study to explore the efficacy of protease inhibitors given in combination with reverse transcriptase inhibitors to HIV-1 infected subjects with protease mutations selected during therapy with GW433908 containing antiretroviral therapy
APV40003 Completed Safety and efficacy of GW433908 in antiretroviral combination therapy in patients with HIV infection
APV40004 Completed Expanded access programme of Fosamprenavir (GW433908) /ritonavir for patients infected by HIV.
APV40005 Completed An open-label phase III study to provide access to fosamprenavir and to assess the long term safety and tolerability of fosamprenavir containing regimens in HIV Infected patients with limited treatment options
APV40006 Completed GW433908 Open Label Study for Subjects with HIV who are Treatment Experienced, on a Failing Regimen or Intolerant to Current Therapy and Sensitive to GW433908
APVF3002 Completed Multicentre, open label, pilot study to evaluate genotypic sensitivity score of fosamprenavir (700mg) in combination with ritonavir (100mg) twice daily, in human immunodeficiency virus (HIV) infected patients with virological escape after first line treatment with a protease inhibitor (PI).
APVF3031 Completed Multicentre, randomized, comparative, open, pilot study to assess efficacy and safety of a treatment with two protease inhibitors (GW433908 + Indinavir [IDV, Crixivan]) boosted by ritonavir in combination with nucleoside reverse transcriptase inhibitor (NRTI) in experienced HIV-1 infected subjects.
APVF3032 Completed Efficacy and pharmacologic evaluation at week 4 of fosamprenavir/ritonavir BID in HIV, pretreated patients switching from amprenavir/ritonavir with controlled plasma viremia.
AR3106116 Completed Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism (VTE) after Abdominal Surgery



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.